Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Overview of attention for article published in The Lancet, April 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news: 14 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 174 X users
patent: 21 patents
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page
f1000: 1 research highlight platform
guideline: 1 clinical guideline source
bluesky: 1 Bluesky user
podcasts: 1 podcast

Readers on

mendeley: 436 Mendeley

So far, Altmetric has seen 17 news stories from 14 outlets.

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease | Cardiovascular Diabetology

Health Reporter, 16 Sep 2023

Treatment With Atrasentan Improves Albuminuria in Patients With Chronic Kidney Disease, Diabetes

Pharmacy Times, 09 Dec 2022

Atrasentan has been found to lower albuminuria, which correlates with reductions in low-density lipoprotein cholesterol and…

Imagine Halting Progression of Kidney Disease in Patients with Type 2 Diabetes

Doc Wire News, 11 Apr 2022

From the Chair Nearly one-half of all patients with kidney failure requiring dialysis have diabetes as the cause of the kidney…

Aduro, Chinook ink merger to take renal drug into phase 3

Fierce Biotech, 03 Jun 2020

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 13 additional news stories.